Metolazone Tablet
NDC Package 0904-7520-61
Package Information
Metolazone tablets are indicated for the treatment of salt and water retention including:• edema accompanying congestive heart failure; • edema accompanying renal diseases, including the nephrotic syndrome and states of diminished renal function.Metolazone tablets are also indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class. MYKROX Tablets, a more rapidly available form of metolazone, are intended for the treatment of new patients with mild to moderate hypertension. A dose titration is necessary if MYKROX Tablets are to be substituted for metolazone tablets in the treatment of hypertension. See package circular for MYKROX Tablets. This formulation utilizes a tablet delivery system. Marketed by Major Pharmaceuticals, this product is identified by NDC 0904-7520 and is authorized under FDA application ANDA215616.
Identification & Billing
- RxCUI: 197979 - metOLazone 2.5 MG Oral Tablet
- RxCUI: 197979 - metolazone 2.5 MG Oral Tablet
- RxCUI: 311671 - metOLazone 5 MG Oral Tablet
- RxCUI: 311671 - metolazone 5 MG Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 0904 - Major Pharmaceuticals
- 0904-7520 - Metolazone
- 0904-7520-61 - 100 BLISTER PACK in 1 CARTON / 1 TABLET in 1 BLISTER PACK
- 0904-7520 - Metolazone
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0904-7520-61 identifies a specific commercial package of 100 blister pack in 1 carton / 1 tablet in 1 blister pack of Metolazone, a human prescription drug labeled by Major Pharmaceuticals. This tablet is formulated for oral use and contains metolazone as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Major Pharmaceuticals on November 20, 2025. The current certification is valid through December 31, 2026.
How is this Major Pharmaceuticals product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00904752061. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 100 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.